JPWO2019155399A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019155399A5 JPWO2019155399A5 JP2020542790A JP2020542790A JPWO2019155399A5 JP WO2019155399 A5 JPWO2019155399 A5 JP WO2019155399A5 JP 2020542790 A JP2020542790 A JP 2020542790A JP 2020542790 A JP2020542790 A JP 2020542790A JP WO2019155399 A5 JPWO2019155399 A5 JP WO2019155399A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound
- hydroxy
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628350P | 2018-02-09 | 2018-02-09 | |
| US62/628,350 | 2018-02-09 | ||
| US201862651796P | 2018-04-03 | 2018-04-03 | |
| US62/651,796 | 2018-04-03 | ||
| US201862782408P | 2018-12-20 | 2018-12-20 | |
| US62/782,408 | 2018-12-20 | ||
| PCT/IB2019/050993 WO2019155399A1 (en) | 2018-02-09 | 2019-02-07 | Tetrahydroquinazoline derivatives useful as anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513534A JP2021513534A (ja) | 2021-05-27 |
| JPWO2019155399A5 true JPWO2019155399A5 (sh) | 2022-02-10 |
| JP7270630B2 JP7270630B2 (ja) | 2023-05-10 |
Family
ID=65724485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542790A Active JP7270630B2 (ja) | 2018-02-09 | 2019-02-07 | 抗癌剤として有用なテトラヒドロキナゾリン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10590115B2 (sh) |
| EP (1) | EP3749665A1 (sh) |
| JP (1) | JP7270630B2 (sh) |
| CA (1) | CA3090482C (sh) |
| TW (1) | TW201942116A (sh) |
| UY (1) | UY38076A (sh) |
| WO (1) | WO2019155399A1 (sh) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7039489B2 (ja) | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| CN111989321B (zh) | 2017-11-15 | 2024-05-14 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| JP6928185B2 (ja) * | 2018-08-16 | 2021-09-01 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 縮合環化合物 |
| JP2022520079A (ja) | 2019-02-12 | 2022-03-28 | ノバルティス アーゲー | Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ |
| WO2021037018A1 (zh) * | 2019-08-26 | 2021-03-04 | 南京创济生物医药有限公司 | 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用 |
| US20220389021A1 (en) * | 2019-09-29 | 2022-12-08 | Beigene, Ltd. | Inhibitors of kras g12c |
| MX2022005053A (es) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Inhibidores de peque?as moleculas de mutante g12c de kras. |
| TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| BR112022008565A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras |
| CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
| TWI760919B (zh) * | 2019-11-15 | 2022-04-11 | 大陸商四川海思科製藥有限公司 | 一種嘧啶並環衍生物及其在醫藥上的應用 |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| JP7480298B2 (ja) * | 2019-12-02 | 2024-05-09 | シャンハイ インリー ファーマシューティカル カンパニー リミテッド | 酸素含有複素環化合物、その製造方法及び使用 |
| CN112979664B (zh) * | 2019-12-02 | 2024-03-01 | 上海璎黎药业有限公司 | 一种含氧杂环化合物、其制备方法及应用 |
| CN112094269B (zh) * | 2020-01-01 | 2021-12-07 | 上海凌达生物医药有限公司 | 一类饱和六元环并杂环类化合物、制备方法和用途 |
| TWI770760B (zh) * | 2020-01-08 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 螺環四氫喹唑啉 |
| GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| CA3232127A1 (en) | 2020-03-12 | 2021-09-16 | D3 Bio (Wuxi) Co., Ltd. | Pyrimidoheterocyclic compounds and application thereof |
| WO2021216770A1 (en) * | 2020-04-22 | 2021-10-28 | Accutar Biotechnology Inc. | Substituted tetrahydroquinazoline compounds as kras inhibitors |
| TWI811656B (zh) * | 2020-04-22 | 2023-08-11 | 大陸商德昇濟醫藥（無錫）有限公司 | 嘧啶并雜環類化合物及其應用 |
| WO2021244603A1 (en) * | 2020-06-04 | 2021-12-09 | Shanghai Antengene Corporation Limited | Inhibitors of kras g12c protein and uses thereof |
| WO2021248095A1 (en) * | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021248082A1 (en) * | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| US20230023009A1 (en) * | 2020-06-05 | 2023-01-26 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| JP2023530351A (ja) | 2020-06-18 | 2023-07-14 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｒａｓ阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法 |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| AU2021345111A1 (en) | 2020-09-15 | 2023-04-06 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| WO2022109485A1 (en) * | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022171013A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 四氢喹唑啉类化合物 |
| MX2023013084A (es) | 2021-05-05 | 2023-11-17 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer. |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US20020025968A1 (en) * | 1998-04-15 | 2002-02-28 | Rifat Pamukcu | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives |
| WO2013026900A1 (en) * | 2011-08-23 | 2013-02-28 | Syngenta Participations Ag | Pyridine derivatives as microbiocides |
| AU2013292309B2 (en) | 2012-07-20 | 2017-05-25 | Cleave Biosciences, Inc. | Fused pyrimidines as inhibitors of p97 complex |
| US10280169B2 (en) | 2013-12-11 | 2019-05-07 | Biogen Ma Inc. | Biaryl bruton's tyrosine kinase inhibitors |
| CN108779097A (zh) | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法 |
| JP7039489B2 (ja) | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
-
2019
- 2019-01-31 TW TW108103754A patent/TW201942116A/zh unknown
- 2019-02-01 US US16/265,012 patent/US10590115B2/en active Active
- 2019-02-07 EP EP19710144.7A patent/EP3749665A1/en not_active Withdrawn
- 2019-02-07 WO PCT/IB2019/050993 patent/WO2019155399A1/en unknown
- 2019-02-07 JP JP2020542790A patent/JP7270630B2/ja active Active
- 2019-02-07 UY UY38076A patent/UY38076A/es not_active Application Discontinuation
- 2019-02-07 CA CA3090482A patent/CA3090482C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019155399A5 (sh) | ||
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| TW200635585A (en) | Monocyclic substituted methanones | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
| JP2012526728A5 (sh) | ||
| PE20081532A1 (es) | Compuestos novedosos | |
| NO20081074L (no) | Macrocyclisk inhibitorer av hepatitis C-virus | |
| JP2018531981A5 (sh) | ||
| JP2012523457A5 (sh) | ||
| JP2010524932A5 (sh) | ||
| EA201101492A1 (ru) | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций | |
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| JP2008535903A5 (sh) | ||
| JP2006505543A5 (sh) | ||
| PE20060602A1 (es) | Derivados de heteroaril acil pirrolidina como inhibidores del virus de la hepatitis c (hcv) | |
| ATE503746T1 (de) | Neue imidazolidinderivate | |
| NO20070258L (no) | Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer | |
| NZ590355A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| JP2018502148A5 (sh) | ||
| WO2009081152A3 (en) | Antimicrobial compounds | |
| RU2011102396A (ru) | Аминосоединения и их медицинское применение | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| WO2009158257A3 (en) | Fungicidal pyridines | |
| PE20141201A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) |